EUVIMEDEUVIMED entdecken
Crossref

Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis

Elma Dema, Christian Dascalescu, Adrien Holzgreve, Clemens C Cyran, Liam Widjaja, Franz Josef Gildehaus, Felix L Herr, Christine Spitzweg, Christoph J Auernhammer, Michael Ingrisch, Matthias Brendel, Jens Ricke und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8621-8629

DOI: 10.1007/s00259-026-08182-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 17.09.2026. Verfasst von Elma Dema und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU University Hospital, LMU Medizin,LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Body Composition, Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms. Die Arbeit nennt 20 Literaturangaben. Gefördert von: MCSP, DFG, FöFoLe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Early progression after PRRT occurs in a subset of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Associations between body composition and early PET-based progression after PRRT were assessed.

Methods

In this retrospective analysis, 321 patients undergoing PRRT were screened. Body composition parameters were assessed on the CT component at the L3/L4 level. Myosteatosis was defined using BMI-adjusted psoas muscle attenuation cut-offs. The primary endpoint was early SSTR-targeted PET-based progression after up to four consecutive PRRT cycles, dichotomized as progressive disease versus disease control, which was available in 301 patients.

Results

Early PET-based progression occurred in 24/301 patients (8.0%). Traditional quantity-based body composition parameters were not associated with early progression. Baseline myosteatosis was present in only 8/301 patients (2.7%) and showed a nominal association with early progression in univariable analysis (OR 7.8, 95% CI 1.74–34.78; p = 0.0073), but this association did not remain significant after Benjamini–Hochberg correction for multiple testing (FDR-adjusted p = 0.1073). In a separately specified baseline-adjusted model, myosteatosis remained nominally associated with early progression (OR 8.1, 95% CI 1.69–38.75; p = 0.0090). In an exploratory model additionally including the number of completed PRRT cycles as a post-baseline treatment-exposure variable, the association was attenuated and narrowly missed conventional statistical significance (OR 5.7, 95% CI 0.97–32.86; p = 0.0538).

Conclusion

Traditional quantity-based body composition parameters were not associated with early PET-based progression after PRRT. Although baseline myosteatosis showed a nominal association with early progression, this finding was based on only eight patients and did not remain significant after correction for multiple testing. The results should therefore be regarded as exploratory and hypothesis-generating and do not establish clinical utility of myosteatosis for individual risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body CompositionNeuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsReceptors, SomatostatinHumansFemaleRetrospective StudiesMaleDisease ProgressionMiddle AgedTreatment OutcomeAgedPositron-Emission TomographyIntestinal Neoplasms

Stichwörter der Autor:innen

Body compositionEarly progressionMyosteatosisNETPRRT

Substanzen

Receptors, Somatostatin

Autor:innen und Institutionen

  • Department of Nuclear Medicine, LMU University Hospital, LMU Medizin,LMU Munich, Munich, Germany.
  • Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Department of Internal Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
  • ENETS Certified Center of Excellence), Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET- KUM, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
  • Interfaculty Centre for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), LMU University Hospital, LMU Medizin, LMU Munich, Marchioninistr. 15, 81377 , Munich, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Förderung

  • MCSP
  • DFG
  • FöFoLe

Zitieren

APA

Dema, E., Dascalescu, C., Holzgreve, A., Cyran, C. C., Widjaja, L., Gildehaus, F. J., Herr, F. L., Spitzweg, C., Auernhammer, C. J., Ingrisch, M., Brendel, M., Ricke, J., Werner, R. A., & Siegmund, S. C. (2026). Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8621-8629. https://doi.org/10.1007/s00259-026-08182-w

Vancouver

Dema E, Dascalescu C, Holzgreve A, Cyran CC, Widjaja L, Gildehaus FJ, et al. Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8621-8629. doi:10.1007/s00259-026-08182-w

BibTeX
@article{Dema2026,
  author = {Dema, Elma and Dascalescu, Christian and Holzgreve, Adrien and Cyran, Clemens C and Widjaja, Liam and Gildehaus, Franz Josef and Herr, Felix L and Spitzweg, Christine and Auernhammer, Christoph J and Ingrisch, Michael and Brendel, Matthias and Ricke, Jens and Werner, Rudolf A and Siegmund, Sophie Carina},
  title = {Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8621--8629},
  doi = {10.1007/s00259-026-08182-w}
}
Kostenlos starten →